EconSight News
AI-based Drug Discovery
AI-based Drug Discovery The AI Drug Discovery Ecosystem Top Players (Patents, 2025) Competition, Collaboration, and Convergence AI-driven drug discovery has become one of the most powerful trends in Pharma and Biotech. Patent activity has doubled over the past two years, reflecting the enormous expectations placed on AI to accelerate R&D. By predicting promising targets and molecules before costly lab work begins, AI explores vastly larger chemical spaces and identifies safety or efficacy risks earlier - reducing time, cost, and late-stage failures. That said, the narrative is maturing: the industry is shifting from [...]
Quantum ETF for BlackRock
New Quantum Computing ETF launched going beyond patents New BlackRock Quantum ETF First to Combine Patents, Company Websites, and Business Reports to Identify Leading Companies The BlackRock iShares Quantum Computing UCITS ETF identifies companies driving the quantum computing ecosystem - from quantum processors to enabling hardware and software - while also capturing firms engaged in cutting-edge exploratory research that advances the field. EconSight worked closely with Stoxx and BlackRock on the development of the index. For the first time, a new approach covering all corporate disclosures was applied, developed by EconSight together with its [...]
EconSight ETFs reach 1.6 billion in assets under management
From Insight to Impact: USD 1.6 Billion in EconSight Technologies - based ETF Assets We’re proud to announce that the EconSight technology classification based ETFs we have developed with our index clients have surpassed USD 1.6 billion in assets under management in January 2026! This milestone proves that patent based technologies intelligence isn’t just for R&D — it’s a powerful tool for identifying and investing in the world’s most innovative companies. In partnership with our clients, we’ve built indexes that underlie ETFs that capture innovation across Digitization, Sustainability, and Security. Artificial Intelligence Quantum Computing Metaverse [...]
Future Water ETF for Deka
New Future Water ETF Joint presentation of the new Deka Future Water ETF FONDS professionell Congress presentation Deka and EconSight jointly presented the new Deka STOXX Future Water ETF at the FONDS professionell Congress. The ETF comprises around 60 companies with involvement in the water sector, including water utilities, firms engaged in water treatment and water desalting, as well as those developing equipment and infrastructure essential to water management. The patent analysis highlights the technological trends: modern filtration technologies and disinfection processes, new digital process and control methods for more [...]
EconSight Gamechanger Index officially launched
EconSight Gamechanger Index officially launched EconSight Gamechanger Index available on Bloomberg The EconSight Global Gamechanger Index showcases the 25 most innovative companies We are proud to announce the launch of the EconSight Global Gamechanger Index, which highlights the potential of patent-based investing in leading innovative companies. Since 29 December 2025, the index has been independently calculated, updated live every 15 minutes, and published on Bloomberg for transparent market access. Ticker: ECONGCI; ISIN: CH1487684362 The strategy has been available on our website as a model portfolio since 2024, and the index has been back-calculated [...]
Industrial AI
Industrial AI Top Industrial AI Companies: Siemens in the Lead EconSight's contribution at the World Economic Forum in Davos 2026 From a technological perspective, this year's World Economic Forum in Davos is all about AI, especially applications. In our talks, we tried to shift the focus from consumer AI to concrete real-world applications, especially industrial AI. The chart that attracted the most attention was clearly the ranking of the best companies in industrial AI. Contrary to general expectations, Siemens, a European company, leads the way, with Bosch and ABB also in [...]
Top Companies in GenAI
The World of GenAI - Top Companies in Generative AI The World of GenAI - Top Companies in Generative AI The World of GenAI - Top Companies in Generative AI View animation full screen The world of GenAI in one chart – Alphabet leads Tencent and Baidu in world-class GenAI patents The chart shows all companies worldwide with at least four GenAI patents and their development over the past ten years. The colour coding makes clear that GenAI activity [...]
China Tech Focus in new 5-year plan
China technology focus in new 5-year plan for 2026-2030 China position in strategic technologies As part of the recommendations for the next five-year plan, China has outlined its technology priorities for the near future. The technologies themselves are not a big surprise. However, the documents and statements of the last few days reveal a stronger focus on innovation quality. From a patent perspective, this is understandable, which is why we are showing here where China stands in these focus technologies compared to the US and Europe in terms of world-class patents. China is a leader [...]
Genmab after Merus acquisition
Genmab after Merus acquisition Genmab strengthens position among global immunotherapy leaders with Merus acquisition From a patent perspective, the acquisition represents a highly strategic move. Genmab now advances to position 25 among the leading immunotherapy companies, measured by the number of world-class patents. This transaction further strengthens Genmab’s already robust market position. Roche and Bristol Myers Squibb remain industry leaders. When focusing on specialized immunotherapy companies—those with more than half of their patents in this field—the acquisition elevates Genmab into the global top 5, ranking just behind Incyte and BioNTech. For [...]
Deloitte Study
Deloitte-EconSight Study Where does Germany stand in global technology competition? Deloitte and EconSight partnered on a new study The Deloitte study ‘Digital Technologies Made in Germany’ highlights Germany's position in global competition for advanced digitalisation technologies and shows ways in which innovative strength can be strengthened in this country. With a view to the high-tech agenda announced by the German government, this study provides an overview of Germany's position in global technology competition and highlights opportunities and untapped potential, as well as recommendations for action for government stakeholders. Based on [...]
Q&A with EconSight and STOXX
Thematic Investing - Q&A with EconSight and STOXX Q&A with EconSight and STOXX: Navigating the patents landscape in emerging AI technologies In this behind-the-scenes look, you can learn more about how EconSight and STOXX recently teamed up to develop two indices targeting leading companies in specific segments of AI adoption: STOXX Global AI Infrastructure and STOXX Global AI Adopters and Applications. The two indices form the basis for corresponding ETFs from BlackRock iShares. Read the STOXX Blog (external link)
BioNTech and CureVac after takeover
BioNTech and CureVac after takeover BioNTech among top players in mRNA and vaccines after CureVac acquisition The planned acquisition of CureVac announced yesterday makes strategic sense for BioNTech. BioNTech justifies the acquisition with its improved positioning in mRNA technologies. EconSight can confirm this from a patent perspective. In terms of world-class patents in mRNA technologies, BioNTech ranks third after the CureVac acquisition with 141 world-class patents, behind Moderna (252 world-class patents) and 10x Genomics (166 world-class patents). Without a world-class focus, i.e. based [...]
AI-based Drug Discovery
AI-based Drug Discovery The AI Drug Discovery Ecosystem Top Players (Patents, 2025) Competition, Collaboration, and Convergence AI-driven drug discovery has become one of the most powerful trends in Pharma and Biotech. Patent activity has doubled over the past two years, reflecting the enormous expectations placed on AI to accelerate R&D. By predicting promising targets and molecules before costly lab work begins, AI explores vastly larger chemical spaces and identifies safety or efficacy risks earlier - reducing time, cost, and late-stage failures. That said, the narrative is maturing: the industry is shifting from [...]
Quantum ETF for BlackRock
New Quantum Computing ETF launched going beyond patents New BlackRock Quantum ETF First to Combine Patents, Company Websites, and Business Reports to Identify Leading Companies The BlackRock iShares Quantum Computing UCITS ETF identifies companies driving the quantum computing ecosystem - from quantum processors to enabling hardware and software - while also capturing firms engaged in cutting-edge exploratory research that advances the field. EconSight worked closely with Stoxx and BlackRock on the development of the index. For the first time, a new approach covering all corporate disclosures was applied, developed by EconSight together with its [...]
EconSight ETFs reach 1.6 billion in assets under management
From Insight to Impact: USD 1.6 Billion in EconSight Technologies - based ETF Assets We’re proud to announce that the EconSight technology classification based ETFs we have developed with our index clients have surpassed USD 1.6 billion in assets under management in January 2026! This milestone proves that patent based technologies intelligence isn’t just for R&D — it’s a powerful tool for identifying and investing in the world’s most innovative companies. In partnership with our clients, we’ve built indexes that underlie ETFs that capture innovation across Digitization, Sustainability, and Security. Artificial Intelligence Quantum Computing Metaverse [...]
Future Water ETF for Deka
New Future Water ETF Joint presentation of the new Deka Future Water ETF FONDS professionell Congress presentation Deka and EconSight jointly presented the new Deka STOXX Future Water ETF at the FONDS professionell Congress. The ETF comprises around 60 companies with involvement in the water sector, including water utilities, firms engaged in water treatment and water desalting, as well as those developing equipment and infrastructure essential to water management. The patent analysis highlights the technological trends: modern filtration technologies and disinfection processes, new digital process and control methods for more [...]
EconSight Gamechanger Index officially launched
EconSight Gamechanger Index officially launched EconSight Gamechanger Index available on Bloomberg The EconSight Global Gamechanger Index showcases the 25 most innovative companies We are proud to announce the launch of the EconSight Global Gamechanger Index, which highlights the potential of patent-based investing in leading innovative companies. Since 29 December 2025, the index has been independently calculated, updated live every 15 minutes, and published on Bloomberg for transparent market access. Ticker: ECONGCI; ISIN: CH1487684362 The strategy has been available on our website as a model portfolio since 2024, and the index has been back-calculated [...]
Industrial AI
Industrial AI Top Industrial AI Companies: Siemens in the Lead EconSight's contribution at the World Economic Forum in Davos 2026 From a technological perspective, this year's World Economic Forum in Davos is all about AI, especially applications. In our talks, we tried to shift the focus from consumer AI to concrete real-world applications, especially industrial AI. The chart that attracted the most attention was clearly the ranking of the best companies in industrial AI. Contrary to general expectations, Siemens, a European company, leads the way, with Bosch and ABB also in [...]
Top Companies in GenAI
The World of GenAI - Top Companies in Generative AI The World of GenAI - Top Companies in Generative AI The World of GenAI - Top Companies in Generative AI View animation full screen The world of GenAI in one chart – Alphabet leads Tencent and Baidu in world-class GenAI patents The chart shows all companies worldwide with at least four GenAI patents and their development over the past ten years. The colour coding makes clear that GenAI activity [...]
China Tech Focus in new 5-year plan
China technology focus in new 5-year plan for 2026-2030 China position in strategic technologies As part of the recommendations for the next five-year plan, China has outlined its technology priorities for the near future. The technologies themselves are not a big surprise. However, the documents and statements of the last few days reveal a stronger focus on innovation quality. From a patent perspective, this is understandable, which is why we are showing here where China stands in these focus technologies compared to the US and Europe in terms of world-class patents. China is a leader [...]
Genmab after Merus acquisition
Genmab after Merus acquisition Genmab strengthens position among global immunotherapy leaders with Merus acquisition From a patent perspective, the acquisition represents a highly strategic move. Genmab now advances to position 25 among the leading immunotherapy companies, measured by the number of world-class patents. This transaction further strengthens Genmab’s already robust market position. Roche and Bristol Myers Squibb remain industry leaders. When focusing on specialized immunotherapy companies—those with more than half of their patents in this field—the acquisition elevates Genmab into the global top 5, ranking just behind Incyte and BioNTech. For [...]
Deloitte Study
Deloitte-EconSight Study Where does Germany stand in global technology competition? Deloitte and EconSight partnered on a new study The Deloitte study ‘Digital Technologies Made in Germany’ highlights Germany's position in global competition for advanced digitalisation technologies and shows ways in which innovative strength can be strengthened in this country. With a view to the high-tech agenda announced by the German government, this study provides an overview of Germany's position in global technology competition and highlights opportunities and untapped potential, as well as recommendations for action for government stakeholders. Based on [...]
Q&A with EconSight and STOXX
Thematic Investing - Q&A with EconSight and STOXX Q&A with EconSight and STOXX: Navigating the patents landscape in emerging AI technologies In this behind-the-scenes look, you can learn more about how EconSight and STOXX recently teamed up to develop two indices targeting leading companies in specific segments of AI adoption: STOXX Global AI Infrastructure and STOXX Global AI Adopters and Applications. The two indices form the basis for corresponding ETFs from BlackRock iShares. Read the STOXX Blog (external link)
BioNTech and CureVac after takeover
BioNTech and CureVac after takeover BioNTech among top players in mRNA and vaccines after CureVac acquisition The planned acquisition of CureVac announced yesterday makes strategic sense for BioNTech. BioNTech justifies the acquisition with its improved positioning in mRNA technologies. EconSight can confirm this from a patent perspective. In terms of world-class patents in mRNA technologies, BioNTech ranks third after the CureVac acquisition with 141 world-class patents, behind Moderna (252 world-class patents) and 10x Genomics (166 world-class patents). Without a world-class focus, i.e. based [...]